“Investing in our global healthcare business in Bangalore is an important step in supporting our pharmaceutical, over-the-counter and medical device customers aligned with anticipated market needs,” said Tom Salmon, President and CEO of BerryGlobal. “During the pandemic, we have learned that strategically placed facilities around the world provide efficient localized support for customers of all sizes. We believe this investment significantly benefits patient populations in India and South Asia.
The addition of the Berry Healthcare site in Bangalore provides extensive technical experience and a steady pipeline of future talent through its network of universities. Building on the company’s established healthcare expertise will enable the continued development of innovative solutions for existing and new applications while improving the patient experience for medication delivery and maintaining functionality highest in areas such as ease of use, dosage control and effective drug protection.
Among its development work, Berry will continue to focus on its current leadership in inhalation devices, including models with digital capabilities and the next generation of injectable devices. Another core business area will be the introduction of innovations in nasal and ophthalmic spray pumps and healthcare packaging for various products.
In addition to high-quality precision manufacturing equipment, the new facility will also house a dedicated R&D Center of Excellence. As well as ensuring that drug dosing and administration is both easy and comfortable for the user, another key design criteria will be to support customers’ sustainability goals, with the existing facility in Bangalore already accredited. International Sustainability and Carbon Certificate (ISCC) Plus. This allows Berry to sell ISCC-certified plastic packaging and components that contribute to a circular economy approach based on advanced recycling and mass balance. The mass balance approach tracks the amount and sustainability characteristics of circular and/or bio-based content in the value chain and assigns it based on verifiable accounting, according to the ISCC organization.
Construction of the new facility is expected to begin later this year, with the site validated and ready for production by summer 2023.
Berry Healthcare’s existing facility in Bangalore was opened in 2009. It is the market leader in ophthalmic and child-resistant closures in India and also produces the user-independent eye drops Risdrop, winner of the Best Innovation award at the CPhI China.